Research Use Only. Melanotan I is sold as a chemical reagent for in-vitro laboratory research, not for human or veterinary use. It is not a drug, supplement, or compounded preparation. It must be handled by qualified professionals. Wholesale Peptide Supply is not a pharmacy or compounding facility under 503A or 503B.
Wholesale Melanotan I — Bulk Research Supply
Also written Melanotan 1, MT-1 or MT1.
Available sizes
In-stock orders ship same day when paid by 1 pm PT, Mon–Fri. Overnight available.
Buy Melanotan I wholesale and in bulk from a US-based research peptide supplier. Every lot is sourced in the USA and third-party tested, with the lab and method on each lot's certificate. Bulk Melanotan I is quoted by dose and volume from a 3-kit (30-vial) order minimum, mix and match across doses and compounds; lower prices are earned at 10 kits and again at 100 kits in the order, mix and match.
Melanotan I (afamelanotide) is a 13-amino-acid analog of α-melanocyte stimulating hormone, [Nle⁴, D-Phe⁷]-α-MSH. It is studied as a melanocortin-1 receptor agonist in laboratory pigmentation and photoprotection models.

Wholesale Catalog
Available Doses
Published per-vial wholesale pricing for Melanotan I. Sold in kits of 10 vials with a 3-kit (30-vial) order minimum, mix and match across doses and compounds; lower prices apply at 10 kits and at 1,000+ vials in the order. Contact us for larger or custom-volume quotes — answered the same day. Urgent? Text or call (714) 625-9215 — you’ll reach a real person in the United States, not a chatbot or an overseas call center.
Melanotan I 10mg
WPSMT110 · CAS 75921-69-6 · Melanocortin Peptides
- 1–9 kits
- $14.38/vial card
$17.97wire/ACH/Zelle - 10–99 kits
- $11.50/vial card
$14.38wire/ACH/Zelle - 100+ kits
- $9.20/vial card
$11.50wire/ACH/Zelle
20% off with cardEarly Black Friday Sale: 20% off every order paid by card
Every product, every volume band — taken off your total at checkout when you choose card. Ends Wed, Nov 25
Sold in kits of 10 vials · 3-kit order minimum, mix and match · price set by the total kits in your order (BAC water not counted)
Questions? Text a rep or call (714) 625-9215 — a real person in the US answers.
Overview
Melanotan I (afamelanotide) is a 13-amino-acid analog of α-melanocyte stimulating hormone, [Nle⁴, D-Phe⁷]-α-MSH. It is studied as a melanocortin-1 receptor agonist in laboratory pigmentation and photoprotection models.
History
Developed from α-MSH with norleucine and D-phenylalanine substitutions that resist enzymatic degradation and increase receptor affinity relative to the native hormone. It is the more MC1R-selective counterpart to Melanotan II.
Melanotan I and Melanotan II are not interchangeable
Both are α-MSH analogues and the names are one numeral apart, which is why they are among the most commonly mis-ordered pair in the melanocortin category.
Melanotan I (afamelanotide) is a linear 13-residue peptide, [Nle⁴, D-Phe⁷]-α-MSH — the native α-MSH sequence with two substitutions that resist enzymatic breakdown. It is substantially selective for MC1R. Melanotan II is a cyclic heptapeptide and is nonselective, engaging MC1R, MC3R, MC4R and MC5R alike.
Selectivity is the reason to choose this one. Pigmentation and photoprotection models that need MC1R signalling studied without concurrent MC3R, MC4R and MC5R activity use Melanotan I precisely because the broader agonist would introduce those pathways as confounds.
The two are complements in a receptor-selectivity comparison, not substitutes in a protocol.
Handling
At 13 residues and linear, Melanotan I is more susceptible to surface adsorption at dilute working concentrations than the cyclic analogue, so low-binding labware is the usual precaution when preparing dilute solutions.
The compound ships lyophilised and is reconstituted with bacteriostatic or sterile water added down the vial wall and swirled gently. Lyophilised material is held at -20°C protected from light; reconstituted solution is refrigerated at 2-8°C. General reagent handling guidance only, not human or veterinary use instruction.
Where Melanotan I's two substitutions came from: Sawyer and Hruby's 1980 PNAS paper
The [Nle⁴, D-Phe⁷] pattern in Melanotan I was not designed from scratch. Tomi Sawyer, Victor Hruby, Mac Hadley and colleagues at the University of Arizona had noticed that α-MSH treated with heat and alkali kept darkening frog skin far longer than the untreated hormone. Gas chromatography showed the treatment had partly racemized the peptide, chiefly at methionine-4 and phenylalanine-7.
They then built that observation into a synthetic peptide. Norleucine replaced methionine-4, removing the oxidizable thioether, and D-phenylalanine replaced L-phenylalanine-7. The resulting [Nle⁴, D-Phe⁷]-α-MSH, published in PNAS in 1980 (77:5754–5758), resisted degradation by serum enzymes and was reported as roughly 26 times as potent as α-MSH at activating mouse melanoma adenylate cyclase, while keeping the prolonged activity seen in the heat-treated hormone. The authors proposed it as a molecular probe for melanotropin receptors on normal and melanoma melanocytes.
The full sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂: all 13 residues of α-MSH with only those two positions changed. That is why the same molecule appears in the literature under three names — NDP-MSH in receptor pharmacology, melanotan-1 in the Arizona program, and afamelanotide as a drug substance.
Afamelanotide: the regulatory record behind the Melanotan I molecule
Early human work on the molecule was run at the University of Arizona Cancer Center under a skin-cancer chemoprevention grant. Levine and colleagues published a randomized, placebo-controlled study in 28 men in JAMA in 1991 (266:2730–2736). The university licensed the molecule in 1995; the Australian company that took it forward, then EpiTan, was renamed Clinuvel in 2006.
Development ended in a rare-disease indication rather than the cosmetic use it began with. Two phase 3 trials in erythropoietic protoporphyria (EPP) — 74 patients in Europe and 93 in the United States — were reported together by Langendonk et al. in the New England Journal of Medicine in 2015 (373:48–59). The European Commission authorized afamelanotide as Scenesse on 22 December 2014 under exceptional circumstances, for prevention of phototoxicity in adults with EPP; its EU orphan designation dated from 8 May 2008 and was withdrawn in December 2024 at the end of the ten-year market exclusivity. The FDA approved Scenesse on 8 October 2019 to increase pain-free light exposure in adults with a history of EPP phototoxic reactions.
That regulatory history belongs to a specific licensed implant formulation, not to research-grade peptide. Material listed here is a laboratory reagent and is not that product; it is supplied for in-vitro research use only and not for human or veterinary use.
Key Areas of Research
- MC1R binding and selectivity across melanocortin receptors
- Melanogenesis and eumelanin pathway models
- Photoprotection research
- Comparative studies vs. Melanotan II and native α-MSH
References
- Sawyer T.K. et al. (1980). 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone. PNAS, 77(10):5754–5758.
- Langendonk J.G. et al. (2015). Afamelanotide for erythropoietic protoporphyria. N Engl J Med, 373(1):48–59.
Melanotan I — Frequently Asked Questions
- What is Melanotan I?
- Melanotan I (afamelanotide) is a 13-amino-acid analog of α-melanocyte stimulating hormone, [Nle⁴, D-Phe⁷]-α-MSH. It is studied as a melanocortin-1 receptor agonist in laboratory pigmentation and photoprotection models.
- What is the CAS number for Melanotan I?
- The CAS number for Melanotan I is 75921-69-6. Its molecular formula is C₇₈H₁₁₁N₂₁O₁₉ (MW 1,646.85 g/mol).
- What doses of Melanotan I are available wholesale?
- Wholesale Peptide Supply stocks Melanotan I in 10mg. Wholesale pricing is provided by quote based on order volume, from a 3-kit (30-vial) order minimum, mix and match across doses and compounds.
- Is Melanotan I third-party tested?
- Yes. Every lot of Melanotan I is tested by an independent third-party laboratory, and a per-lot Certificate of Analysis documenting identity and purity is included with every order at no charge, issued in the name of Wholesale Peptide Supply.
- Is Melanotan I for human use?
- No. Melanotan I is sold strictly as a chemical reagent for in-vitro laboratory research and is not for human or veterinary use. Wholesale Peptide Supply is not a pharmacy or compounding facility.
- How do I get wholesale pricing for Melanotan I?
- Request a quote through our contact form or open a wholesale account. An account manager replies with volume pricing and lead times the same day. For anything urgent, text or call (714) 625-9215 to reach a real person in the US.
- Can I order Melanotan I in bulk?
- Yes. Melanotan I is available for bulk and wholesale orders, quoted by dose and volume, from a 3-kit (30-vial) order minimum, mix and match across doses and compounds, with lower prices at 10 kits and at 100 kits (1,000 vials) in the order. Submit the doses and quantities you need for a bulk quote.
- What is NDP-MSH, and is it the same thing as Melanotan I?
- Yes. NDP-MSH (also written NDP-α-MSH) is the receptor-pharmacology name for [Nle⁴, D-Phe⁷]-α-MSH, the same molecule catalogued here as Melanotan I and developed as afamelanotide. Its iodinated form, [¹²⁵I]NDP-MSH, is the conventional radioligand for labeling MC1R, MC3R, MC4R and MC5R in competition binding assays, which is one reason the molecule turns up in melanocortin papers that are not about pigmentation at all.
- How MC1R-selective is Melanotan I really?
- It prefers MC1R, but the preference is a matter of degree rather than an on/off difference. Binding values compiled by Haitina et al. (BMC Evolutionary Biology, 2007) give NDP-MSH Ki figures of about 0.046 nM at human MC1R, 0.32 nM at MC3R, 1.96 nM at MC4R and 2.39 nM at MC5R — roughly a 40- to 50-fold preference for MC1R over MC4R and MC5R. Designs that need MC3R–MC5R activity excluded generally confirm it with antagonists or receptor-null lines rather than relying on the ligand alone.
- Is Melanotan I linear or cyclic, and how does that compare with Melanotan II?
- Melanotan I is linear: 13 residues, N-acetylated and C-amidated, with no ring. Melanotan II is a cyclic heptapeptide closed by a side-chain-to-side-chain lactam bridge. The practical consequences are that Melanotan I is the longer and heavier molecule (1,646.85 g/mol against 1,024.18) and, being linear and unconstrained, is the more adsorption-prone of the two in dilute solution.
- How many moles are in a 10 mg vial of Melanotan I?
- At the free-peptide molecular weight of 1,646.85 g/mol, 10 mg is about 6.07 µmol. The same mass of Melanotan II is about 9.76 µmol, since that molecule is 7 residues rather than 13. Counter-ion and net peptide content shift the true figure, so comparisons between the two compounds should be calculated on a molar basis rather than matched by vial mass.
Related Compounds
Melanocortin Peptides
Melanotan II
Melanotan II is a synthetic cyclic heptapeptide analog of α-MSH acting as a nonselective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R).
View details →Melanocortin Peptides
PT-141
PT-141 (Bremelanotide) is a synthetic α-MSH analog selective for central MC3R/MC4R activity, studied for neuroendocrine signaling and vascular pathways.
View details →Melanocortin Peptides
Oxytocin
Oxytocin is a cyclic nonapeptide synthesized in hypothalamic neurons. Through OXTR binding, it activates phospholipase C-mediated pathways. Studied for smooth muscle, CNS, and autonomic signaling.
View details →Melanocortin Peptides
Kisspeptin-10
Kisspeptin-10 is the decapeptide Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, corresponding to the bioactive C-terminal residues 45-54 of metastin. It is studied as a KISS1R (GPR54) agonist in laboratory models of neuroendocrine signaling.
View details →GLP Series Peptides
GLP-1S
GLP-1S is a synthetic peptide analog that functions as a long-acting pathway agonist, structurally modified for extended half-life and improved target binding affinity. It is studied in preclinical and laboratory models for its ability to activate target pathways and modulate downstream molecular signaling associated with endocrine regulation.
View details →GLP Series Peptides
GLP-2T
GLP-2T is a synthetic peptide that functions as a dual pathway agonist, designed as a once-weekly investigational compound studied in preclinical laboratory models for receptor-mediated signaling and modulation of downstream cascades.
View details →GLP Series Peptides
GLP-3R
GLP-3R is a synthetic investigational peptide developed as a multi-pathway agonist, representing the next generation of metabolic research compounds. It activates multiple target receptor subtypes for broad systemic effects studied in preclinical models.
View details →Secretagogue Peptides
Ipamorelin
Ipamorelin is a synthetic pentapeptide and selective secretagogue-type agonist with minimal off-target pathway interference, used to study endocrine signaling and somatotroph axis modulation.
View details →